NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY

Profound hearing loss is common in patients with neurofibromatosis 2 (NF2) and vestibular schwannomas (VS). Bevacizumab treatment at 7.5 mg/kg every 3 weeks has been associated with hearing improvement and tumor shrinkage in 36% and 43% of patients, respectively. However, the optimal treatment dose...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Tonsgard, James, Ullrich, Nicole, Blakeley, Jaishri, Rosser, Tena, Packer, Roger, Korf, Bruce, Fisher, Michael, Cutter, Gary, Plotkin, Scott, Karajannis, Matthias, Allen, Jeffrey, Wade Clapp, D, Thomas, Coretta, Campian, Jian
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2018
Предметы:
Abstracts
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012828/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.517
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы